Dear TechNet colleagues,
I am developing the Field Constraint Registry for Vaccine Specification (FCRVS), a practitioner-contributed, curated platform designed to convert recurring vaccine delivery constraints in fragile, conflict-affected, and other operationally constrained settings into structured signals for vaccine product design, procurement strategy, and implementation guidance.
The premise is straightforward: frontline teams routinely encounter delivery barriers that reveal where current product and operational assumptions do not match field realities. These observations are often discussed informally, but they rarely enter a standardized format that is comparable across settings or directly usable by vaccine developers, procurement bodies, or normative institutions. The FCRVS is intended to help close that gap.
The registry builds on the Field-Anchored Vaccine Specification Matrix (FAVSM), a peer-reviewed analytical framework published in 2026 (DOI: 10.5772/intechopen.1014867), which structures field constraints across six domains: thermal environment, infrastructure availability, population mobility, health workforce capacity, governance and ethical-regulatory context, and delivery flexibility. Each registry submission is designed to map practitioner observations to these domains and link them to operational consequences, product implications, and innovation needs.
The concept note is attached and outlines the proposed registry design, minimum data architecture, governance approach, and planned outputs. I would greatly welcome comments and critique on any of these dimensions, particularly the practicality of the submission structure, the proposed analytical outputs, and the potential use cases for immunization programmes, procurement, and product development.
Thank you very much for your time and consideration.
Tambe Elvis Akem, MD MSc MPH
Founder, ImmunizationForResilience Research Group
Author, Field-Anchored Vaccine Specification Matrix (FAVSM)
[email protected]
There are no replies made for this post yet.